Posts by Philip J. Saylor, MD
Primary Prostate Cancer Establishes a Suppressive Immune Microenvironment
Through careful unraveling of the cellular and molecular landscape of prostate cancer, Massachusetts General Hospital researchers observed a highly immune-suppressive tumor microenvironment with a pattern of angiogenic gene expression, findings that will help identify targets amenable to therapeutic interventions.
Subspecialized Care at Mass General for Cancer Metastatic to Bone
The Massachusetts General Hospital's Bone & Spine Metastasis Program offers expert consultation and advanced subspecialty treatment for cancer metastatic to bone.
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
Shenglin Mei, PhD, Philip J. Saylor, MD, David B. Sykes, MD, PhD, and colleagues found that simultaneous expression of four specific genes predicts survival and metastasis in human clear cell renal cell carcinoma, and they identified other potential therapeutic targets.
Philip J. Saylor, MD, is a genitourinary medical oncologist and clinical/translational investigator at the Mass General Cancer Center where he has been an attending physician since 2010. His in-person clinic is located on the Mass General Boston campus in the Yawkey building on the 7th floor (Yawkey 7E clinic area), though he also provides virtual care. He and his team provide collaborative care for patients with genitourinary cancers (prostate, kidney/renal cell, bladder & upper tract urothelial, testicular, and adrenal cancers). His practice is primarily based in the outpatient clinic, but he also works approximately 1 month per year providing hospital-based care.
His research is focused on prostate cancer and other genitourinary cancers with emphases on (1) team-oriented bedside-to-bench collaboration to better understand the biology of the tumor microenvironment, and (2) the metabolic side effects of systemic prostate cancer treatments. Among other efforts, he has worked since 2016 with a diverse coalition of collaborators (clinically-focused physicians, lab investigators focused on tumor biology, and a bio-informatics lab) to study human bone metastasis tissue at the single cell level. It is his belief that this sort of low ego / team-oriented research can accomplish things that wouldn't be possible for any smaller sub-set of the people involved. Improving the lives of patients is the ultimate goal of all of this work.
Dr. Saylor is originally from the San Francisco Bay Area. He earned his MD from the University of Pittsburgh School of Medicine, then completed his internal medicine residency at the University of California San Diego. His fellowship training in medical oncology was at Dana Farber Cancer Institute and Mass General.